What Drugs Work Like Cosentyx for Psoriatic Arthritis?
Cosentyx (secukinumab) is an IL-17A inhibitor approved for psoriatic arthritis (PsA). Similar drugs target the same pathway or related cytokines to reduce joint inflammation and skin symptoms. Key alternatives include:
- Ixifi (ixekizumab, Taltz): Another IL-17A inhibitor from Eli Lilly, FDA-approved for PsA in 2017. It blocks the same protein as Cosentyx, showing comparable efficacy in trials for joint pain and skin clearance.1
- Cympta (brodalumab, Siliq): An IL-17 receptor blocker (not just the A subtype) from Valeant, approved for psoriasis but used off-label or in trials for PsA. It provides broader IL-17 inhibition.2
These match Cosentyx's mechanism most closely, with subcutaneous injections every 4 weeks after loading doses.
How Do TNF Inhibitors Compare as PsA Alternatives?
TNF blockers are a broader class often used before or alongside IL-17 drugs for PsA. They're not identical but frequently prescribed similarly:
| Drug | Maker | Key Notes for PsA |
|------|--------|------------------|
| Enbrel (etanercept) | Amgen | Weekly injections; first TNF approved for PsA (2002). Strong joint data.1 |
| Humira (adalimumab) | AbbVie | Biweekly; broad approvals including PsA skin/joints. Biosimilars available.3 |
| Simponi (golimumab) | Janssen | Monthly; effective for enthesitis (tendon inflammation) common in PsA. |
TNFs preceded IL-17s and remain first-line for many patients due to longer track records.
What About IL-23 or IL-12/23 Inhibitors for PsA?
These target upstream inflammation pathways, offering oral or injection options with PsA approvals:
- Tremfya (guselkumab): Janssen's IL-23 inhibitor, approved 2020. Every 8 weeks; excels in skin psoriasis alongside joints.1
- Rimvoq (upadacitinib): AbbVie's oral JAK inhibitor (not cytokine-specific), approved 2021. Daily pill; faster joint relief in trials vs. biologics.4
- Stelara (ustekinumab): Janssen's IL-12/23 blocker, approved early for PsA. Less frequent dosing (every 12 weeks).2
Patients switch to these if IL-17 drugs like Cosentyx fail, per ACR guidelines prioritizing least burdensome options.
When Do Patients Switch from Cosentyx and What Are the Risks?
Switching occurs if no response after 3-6 months (ACR20 criteria). IL-17s like Cosentyx carry black-box warnings for infections; TNFs add TB reactivation risk. Head-to-head trials (e.g., SPIRIT-H2H) show similar efficacy across classes, but IL-23s may have better long-term skin control.5 Biosimilars for Humira cut costs—check DrugPatentWatch.com for patent expirations on originators like Cosentyx (expires ~2032 US).6
Sources